Baptist Cancer Services offers patients participation in clinical trials. Following are the clinical trials currently available as of June 2014. For more information, contact our Baptist Cancer Services Navigator, Tonya Ball, at 601-974-6238.
Amgen - prospective study of the relationship between chemotherapy dose and mortality in early stage breast cancer
Astra Zeneca-Phase 3 randomized study of Olaparib versus physician's' choice chemotherapy in metastatic breast cancer with germline BRACA 1/2 Mutations.
Novartis - double-blind study of LEE011 with Femara for hormone positive advanced breast cancer with no prior therapy for advanced or metastatic disease
Puma Biotechnology - Neratinib plus Xeloda versus Tykerb plus Xeloda in patients with HER 2 positive metastatic breast cancer who have received two or more regimens for metastatic disease
Sanofi - Observational trial for metastatic colon cancer patients receiving Zaltrap in combination with FOLFIRI
Novartis - study of switching patients who have received Gleevec for one year and achieved a partial response to Tasigna
Bristol Myers Squibb-- Nivolumab in patients with metastatic non-small cell lung cancer who have progression of disease after receiving at least one prior chemotherapy
Novartis - a phase 3 study trial of LGYX818 and MEK 162 and LX818 monotherapy compared with Vemurafenib in metastatic melanoma
Celgene– phase 3 randomized, double-blind study to compare efficacy and safety of Oral Azacitidine versus placebo plus best supportive care in subjects with RBC transfusion dependent anemia and thrombocytopenia due to IPSS lower risk MDS
What can we help you find?